KR100806533B1 - 레트로바이러스성 프로테아제 억제제를 제조하기 위한방법 및 중간체 - Google Patents
레트로바이러스성 프로테아제 억제제를 제조하기 위한방법 및 중간체 Download PDFInfo
- Publication number
- KR100806533B1 KR100806533B1 KR1020037002869A KR20037002869A KR100806533B1 KR 100806533 B1 KR100806533 B1 KR 100806533B1 KR 1020037002869 A KR1020037002869 A KR 1020037002869A KR 20037002869 A KR20037002869 A KR 20037002869A KR 100806533 B1 KR100806533 B1 KR 100806533B1
- Authority
- KR
- South Korea
- Prior art keywords
- reactor
- formula
- contents
- amino
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000543 intermediate Substances 0.000 title abstract description 7
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 230000001177 retroviral effect Effects 0.000 title 1
- AMPWQTJNJASABL-UHFFFAOYSA-N 1,6-diphenylhexan-1-amine Chemical compound C=1C=CC=CC=1C(N)CCCCCC1=CC=CC=C1 AMPWQTJNJASABL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- FOJWLLXWJOVURY-UHFFFAOYSA-N 5-(2,2-dibenzylhydrazinyl)-1,6-diphenylhexan-3-ol Chemical compound OC(CCc1ccccc1)CC(Cc1ccccc1)NN(Cc1ccccc1)Cc1ccccc1 FOJWLLXWJOVURY-UHFFFAOYSA-N 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- -1 2,6-dimethylphenoxyacetyl Chemical group 0.000 abstract description 40
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 description 9
- 239000012279 sodium borohydride Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 0 *N([C@@](Cc1ccccc1)C(C[C@](Cc1ccccc1)N)=O)P Chemical compound *N([C@@](Cc1ccccc1)C(C[C@](Cc1ccccc1)N)=O)P 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004030 hiv protease inhibitor Substances 0.000 description 3
- 229940043131 pyroglutamate Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CVUOJBKULXTCRU-ZETCQYMHSA-N (2s)-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanoyl chloride Chemical compound CC(C)[C@@H](C(Cl)=O)N1CCCNC1=O CVUOJBKULXTCRU-ZETCQYMHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- IVYLNCUETJNNJU-AYRMWSDDSA-N (z,2s)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one Chemical compound O=C([C@H](CC=1C=CC=CC=1)N(CC=1C=CC=CC=1)CC=1C=CC=CC=1)\C=C(/N)CC1=CC=CC=C1 IVYLNCUETJNNJU-AYRMWSDDSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- MTOBBJCWGZMHGE-UHFFFAOYSA-N 2-(2,6-dimethylphenoxy)acetyl chloride Chemical compound CC1=CC=CC(C)=C1OCC(Cl)=O MTOBBJCWGZMHGE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WWIJGHHDQFJHQW-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoyl chloride Chemical compound ClC(=O)C(C)(C)OC1=CC=CC=C1 WWIJGHHDQFJHQW-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (13)
- 화학식 III의 화합물을 불활성 용매 속에서 화학식 V의 화합물과 반응시킴을 포함하는, 화학식 II의 화합물의 제조방법.화학식 II화학식 III화학식 V위의 화학식 II, 화학식 III 및 화학식 V에서,P1 및 P2는 수소 및 N-보호 그룹으로부터 독립적으로 선택되고,R3은 C1-C6-알킬, 하이드록시-C1-C6-알킬 또는 C3-C10-사이클로알킬-C1-C6-알킬(여기서, 사이클로알킬은 1 또는 2개의 환을 갖는다)이고,R4는 이미다졸릴, 피롤릴, 피라졸릴, 1,2,3-트리아졸릴, 1,2,4-트리아졸릴, 테트라졸릴, 인돌릴, 벤즈이미다졸릴 및 벤조트리아졸릴로 이루어진 그룹으로부터 선택된, 환 질소원자를 통해 카보닐 그룹에 결합된 질소 함유 헤테로사이클이다.
- 제1항에 있어서, R4가 이미다졸릴인 방법.
- 제1항에 있어서, P1 및 P2가 각각 벤질이고 R3이 C1-C6-알킬이고 R4가 이미다졸릴인 방법.
- 제1항에 있어서, P1 및 P2가 각각 벤질이고 R3이 이소프로필이고 R4 가 이미다졸릴인 방법.
- 제1항에 있어서, 물을 추가로 포함하는 방법.
- 제5항에 있어서, 물이, 반응 혼합물의 용적에 대한 물의 중량비를 기준으로 하여, 1 내지 3중량/용적%의 양으로 존재하는 방법.
- (2S,3S,5S)-2-N,N-디벤질아미노-3-하이드록시-5-아미노-1,6-디페닐헥산을 불활성 용매 속에서 N-(2S-(1-테트라하이드로-피리미드-2-오닐)-3-메틸부타노일)이미다졸과 반응시킴을 포함하는, (2S,3S,5S)-2-N,N-디벤질아미노-3-하이드록시-5-(2S-(1-테트라하이드로-피리미드-2-오닐)-3-메틸부타노일)아미노-1,6-디페닐헥산 및 (2S,3S,5S)-2-아미노-3-하이드록시-5-(2S-(1-테트라하이드로-피리미드-2-오닐)-3-메틸부타노일)아미노-1,6-디페닐헥산으로부터 선택된 화합물의 제조방법.
- 제7항에 있어서, 물을 추가로 포함하는 방법.
- 제8항에 있어서, 물이, 반응 혼합물의 용적에 대한 물의 중량비를 기준으로 하여, 1 내지 3중량/용적%의 양으로 존재하는 방법.
- 제10항에 있어서, R3이 C1-C6-알킬이고 R4가 이미다졸릴인 화합물.
- 제10항에 있어서, R3이 이소프로필이고 R4가 이미다졸릴인 화합물.
- N-(2S-(1-테트라하이드로-피리미드-2-오닐)-3-메틸부타노일)이미다졸릴인 화합물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65191900A | 2000-08-31 | 2000-08-31 | |
US09/651,919 | 2000-08-31 | ||
PCT/US2001/026898 WO2002018349A2 (en) | 2000-08-31 | 2001-08-29 | Process and intermediates for preparing retroviral protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030061787A KR20030061787A (ko) | 2003-07-22 |
KR100806533B1 true KR100806533B1 (ko) | 2008-02-25 |
Family
ID=24614772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037002869A KR100806533B1 (ko) | 2000-08-31 | 2001-08-29 | 레트로바이러스성 프로테아제 억제제를 제조하기 위한방법 및 중간체 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1313712B1 (ko) |
JP (1) | JP5021141B2 (ko) |
KR (1) | KR100806533B1 (ko) |
CN (1) | CN1264823C (ko) |
AT (1) | ATE361913T1 (ko) |
AU (1) | AU2001286889A1 (ko) |
BR (1) | BR0108146A (ko) |
CA (2) | CA2731273C (ko) |
CY (1) | CY1106738T1 (ko) |
DE (1) | DE60128367T2 (ko) |
DK (1) | DK1313712T3 (ko) |
ES (1) | ES2284684T3 (ko) |
HK (1) | HK1057040A1 (ko) |
IL (1) | IL153436A0 (ko) |
MX (1) | MXPA03001751A (ko) |
PT (1) | PT1313712E (ko) |
WO (1) | WO2002018349A2 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE539074T1 (de) * | 2003-12-11 | 2012-01-15 | Abbott Lab | Die hiv-protease hemmende verbindungen |
CN100358521C (zh) * | 2004-12-28 | 2008-01-02 | 哈尔滨欧替药业股份有限公司 | 一种双唑泰栓剂及其制备工艺 |
CN103910634B (zh) * | 2012-12-29 | 2018-04-27 | 广东东阳光药业有限公司 | 西格列汀中间体的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021685A1 (en) * | 1995-12-13 | 1997-06-19 | Abbott Laboratories | Retroviral protease inhibiting compounds |
-
2001
- 2001-08-29 IL IL15343601A patent/IL153436A0/xx active IP Right Grant
- 2001-08-29 EP EP01966367A patent/EP1313712B1/en not_active Expired - Lifetime
- 2001-08-29 DK DK01966367T patent/DK1313712T3/da active
- 2001-08-29 CA CA2731273A patent/CA2731273C/en not_active Expired - Lifetime
- 2001-08-29 JP JP2002523467A patent/JP5021141B2/ja not_active Expired - Lifetime
- 2001-08-29 KR KR1020037002869A patent/KR100806533B1/ko active IP Right Grant
- 2001-08-29 PT PT01966367T patent/PT1313712E/pt unknown
- 2001-08-29 AT AT01966367T patent/ATE361913T1/de active
- 2001-08-29 BR BR0108146-2A patent/BR0108146A/pt not_active Application Discontinuation
- 2001-08-29 WO PCT/US2001/026898 patent/WO2002018349A2/en active IP Right Grant
- 2001-08-29 CA CA2416955A patent/CA2416955C/en not_active Expired - Lifetime
- 2001-08-29 MX MXPA03001751A patent/MXPA03001751A/es active IP Right Grant
- 2001-08-29 DE DE60128367T patent/DE60128367T2/de not_active Expired - Lifetime
- 2001-08-29 ES ES01966367T patent/ES2284684T3/es not_active Expired - Lifetime
- 2001-08-29 CN CNB018148646A patent/CN1264823C/zh not_active Expired - Lifetime
- 2001-08-29 AU AU2001286889A patent/AU2001286889A1/en not_active Abandoned
-
2003
- 2003-10-17 HK HK03107574A patent/HK1057040A1/xx not_active IP Right Cessation
-
2007
- 2007-07-16 CY CY20071100952T patent/CY1106738T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021685A1 (en) * | 1995-12-13 | 1997-06-19 | Abbott Laboratories | Retroviral protease inhibiting compounds |
Also Published As
Publication number | Publication date |
---|---|
KR20030061787A (ko) | 2003-07-22 |
JP2004507528A (ja) | 2004-03-11 |
ATE361913T1 (de) | 2007-06-15 |
BR0108146A (pt) | 2004-01-06 |
CN1264823C (zh) | 2006-07-19 |
CA2731273C (en) | 2013-10-15 |
IL153436A0 (en) | 2003-07-06 |
JP5021141B2 (ja) | 2012-09-05 |
DE60128367T2 (de) | 2008-01-10 |
MXPA03001751A (es) | 2003-09-10 |
CA2731273A1 (en) | 2002-03-07 |
CN1449388A (zh) | 2003-10-15 |
WO2002018349A2 (en) | 2002-03-07 |
WO2002018349A3 (en) | 2002-05-10 |
CA2416955C (en) | 2011-04-26 |
AU2001286889A1 (en) | 2002-03-13 |
EP1313712A2 (en) | 2003-05-28 |
ES2284684T3 (es) | 2007-11-16 |
DK1313712T3 (da) | 2007-09-10 |
PT1313712E (pt) | 2007-07-25 |
HK1057040A1 (en) | 2004-03-12 |
EP1313712B1 (en) | 2007-05-09 |
CA2416955A1 (en) | 2002-03-07 |
DE60128367D1 (de) | 2007-06-21 |
CY1106738T1 (el) | 2012-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7232902B2 (en) | Process to prepare (1-carboxymethyl)-pyrimidinone compounds | |
KR100806533B1 (ko) | 레트로바이러스성 프로테아제 억제제를 제조하기 위한방법 및 중간체 | |
US6372905B1 (en) | Processes and intermediates for preparing retroviral protease inhibitors | |
CA1310017C (en) | Process for the preparation of 2, 6-dichlorodiphenylamino-acetic acid derivatives | |
US6803467B2 (en) | Intermediates for the production of quinolone carboxylic acid derivatives | |
US5932766A (en) | Process for the preparation of substituted keto-enamines | |
US5461157A (en) | Process for preparing pyrrolidinylacetamide derivatives | |
US5508425A (en) | Process for producing 2-substituted 5-chlorimidazoles | |
US5739399A (en) | Process for the preparation of cyclopropanecarboxylic acid amides | |
EP0574952B1 (en) | Process for preparing 2-oxopyrrolidinylacetamide derivatives | |
US3320272A (en) | Process for preparing z-alkoxycyclo- heptimidazole derivatives | |
US6063962A (en) | Process for the preparation of NMDA antagonists | |
KR100309596B1 (ko) | 2-치환5-클로로이미다졸-4-카르발데히드의제조방법 | |
JP3037399B2 (ja) | イミダゾール誘導体の製法 | |
WO2005063678A1 (ja) | フェニル酢酸誘導体の製造方法 | |
CN118206548A (zh) | [1,2,4]三唑并[1,5-a]吡啶-6-醇的合成方法 | |
WO2022133097A1 (en) | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels | |
KR820000366B1 (ko) | 피롤로-벤조산 유도체의 제조 방법 | |
KR20140019280A (ko) | 디미라세탐의 제조 방법 | |
JPH0478632B2 (ko) | ||
JPH11193286A (ja) | ピリジン誘導体およびその製造方法 | |
JPH0378857B2 (ko) | ||
JPH03279357A (ja) | 新規なn―置換マレイミド及びその製造法 | |
MXPA99005398A (en) | Process for the preparation of nmda antagonists | |
KR20010077046A (ko) | 피롤의 새로운 알킬화 반응 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130130 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140129 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150129 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181227 Year of fee payment: 12 |